Computational modeling for rational design of novel phenoxy tacrine derivatives targeting Alzheimer's disease
Mohamed El Fadili1, Mohammed Er-Rajy1, Somdutt Mujwar2
1LIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Abstract:
Alzheimer's is the leading factor behind dementia, producing steady impairments in memory, cognitive reasoning, behavioral, and social interactions. This scientific study investigates thirty-two phenoxy tacrine (PhO-THA) derivatives through an integrated computational modeling to identify potential therapeutic candidates. 3D-QSAR models were developed using comparative molecular similarity indices analysis and comparative molecular field analysis, which were subjected to rigorous internal and external validation to establish a robust quantitative relationship between molecular interaction fields and cytotoxic activities. Based on these validated structural insights, fourteen new compounds (D1-D14) were designed. Comprehensive molecular docking and molecular dynamics (MD) simulations, coupled with ADME-Tox profiling, were used to evaluate their pharmacological potential. Our results highlight four specific compounds (D9-D12) that exhibit favorable pharmacokinetic properties and a high safety profile, making them promising candidates for future drug development. D9 was selected for MD simulations due to its lower cytotoxic activity (pIC50 of 3.50), which is comparable to the reference THA drug (pIC50 of 3.52). The results demonstrated exceptional thermodynamic stability for D9 upon complexation with the NMDA receptor (PDB ID: 5EWJ) over a 100 ns simulation time.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model


